Compare $NRIX vs $RXRX | Chartloom

Compare

$NRIX vs $RXRX

Nurix Therapeutics Inc · Recursion Pharmaceuticals Inc

NRIX

Nurix Therapeutics Inc

RXRX

Recursion Pharmaceuticals Inc

Compare $NRIX vs $RXRX

Comparing Nurix Therapeutics Inc and Recursion Pharmaceuticals Inc

NRIXNurix Therapeutics Inc

RXRXRecursion Pharmaceuticals Inc

NRIXNurix Therapeutics Inc

Market cap

$2.32B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

24.84x

Rev growth (TTM)

-58.4%

YTD performance

23.8%

52W performance

123.9%

FCF yield

-13.1%

RXRXRecursion Pharmaceuticals Inc

Market cap

$2.31B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

44.44x

Rev growth (TTM)

-15.1%

YTD performance

3.8%

52W performance

-28.4%

FCF yield

-15.2%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

NRIX

RXRX

Detailed metrics comparison

NRIX

Nurix Therapeutics Inc

RXRX

Recursion Pharmaceuticals Inc

Market Cap

NRIX$2.32B

RXRX$2.31B

Enterprise Value

NRIX$2.25B

RXRX$1.78B

Price

NRIX$22.35

RXRX$4.36

P/E Ratio

NRIXN/A

RXRXN/A

P/S Ratio

NRIX63.09x

RXRX42.12x

EV/Sales

NRIX61.25x

RXRX32.43x

EV/EBITDA

NRIX0.00x

RXRX0.00x

P/B Ratio

NRIX5.93x

RXRX2.41x

P/FCF Ratio

NRIXN/A

RXRXN/A

EV/FCF

NRIX-7.39x

RXRX-5.05x

PEG Ratio

NRIXN/A

RXRXN/A

Forward P/E (NTM)

NRIXN/A

RXRXN/A

Forward P/S (NTM)

NRIX24.84x

RXRX44.44x

Revenue (TTM)

NRIX$37M

RXRX$55M

Revenue Growth (YoY)

NRIX-58.4%

RXRX-15.1%

Forward Rev Growth

NRIX66.6%

RXRX31.0%

Gross Margin (TTM)

NRIX0.0%

RXRX3.5%

Operating Margin (TTM)

NRIX0.0%

RXRX0.0%

EBITDA Margin (TTM)

NRIX-959.0%

RXRX-848.9%

Net Margin (TTM)

NRIX-928.4%

RXRX-945.9%

FCF Margin (TTM)

NRIX-828.3%

RXRX-642.2%

Net Income (TTM)

NRIX$-341M

RXRX$-519M

FCF (TTM)

NRIX$-305M

RXRX$-352M

EPS (TTM)

NRIX-$3.07

RXRX-$0.97

ROE (TTM)

NRIX-7609.0%

RXRX-5041.0%

ROA (TTM)

NRIX-5732.0%

RXRX-3825.0%

ROIC (TTM)

NRIX-7609.0%

RXRX-4956.0%

Cash

NRIX$68M

RXRX$546M

Debt

NRIX$0

RXRX$14M

Net Cash/Debt

NRIX$68M

RXRX$531M

Current Ratio (TTM)

NRIX6.34x

RXRX5.03x

Quick Ratio (TTM)

NRIX6.16x

RXRX4.96x

Debt/Equity (TTM)

NRIX0.00x

RXRX0.02x

Debt/Assets (TTM)

NRIX0.0%

RXRX0.0%

Interest Coverage (TTM)

NRIXN/A

RXRXN/A

Net Debt/EBITDA (TTM)

NRIX0.00x

RXRX0.00x

Beta

NRIX1.78

RXRX1.18

52W Performance

NRIX123.9%

RXRX-28.4%

YTD Performance

NRIX23.8%

RXRX3.8%

% from 52W High

NRIX-20.8%

RXRX-39.3%

% from 52W Low

NRIX148.3%

RXRX57.4%

Asset Turnover (TTM)

NRIX0.06x

RXRX0.04x

FCF Yield (TTM)

NRIX-13.1%

RXRX-15.2%

Earnings Yield (TTM)

NRIX-14.7%

RXRX-22.5%

Dividend Yield (TTM)

NRIXN/A

RXRXN/A

Rule of 40

NRIX-886.7

RXRX-657.3

EV/GP/RG

NRIXN/A

RXRX29.99

Ticker research

View NRIX research View RXRX research

Metric	NRIX Nurix Therapeutics Inc	RXRX Recursion Pharmaceuticals Inc
Market & Valuation
Market Cap	$2.32B	$2.31B
Enterprise Value	$2.25B	$1.78B
Price	$22.35	$4.36
P/E Ratio	N/A	N/A
P/S Ratio	63.09x	42.12x
EV/Sales	61.25x	32.43x
EV/EBITDA	0.00x	0.00x
P/B Ratio	5.93x	2.41x
P/FCF Ratio	N/A	N/A
EV/FCF	-7.39x	-5.05x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	24.84x	44.44x
Revenue & Growth
Revenue (TTM)	$37M	$55M
Revenue Growth (YoY)	-58.4%	-15.1%
Forward Rev Growth	66.6%	31.0%
Profitability
Gross Margin (TTM)	0.0%	3.5%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-959.0%	-848.9%
Net Margin (TTM)	-928.4%	-945.9%
FCF Margin (TTM)	-828.3%	-642.2%
Net Income (TTM)	$-341M	$-519M
FCF (TTM)	$-305M	$-352M
EPS (TTM)	-$3.07	-$0.97
ROE (TTM)	-7609.0%	-5041.0%
ROA (TTM)	-5732.0%	-3825.0%
ROIC (TTM)	-7609.0%	-4956.0%
Financial Health
Cash	$68M	$546M
Debt	$0	$14M
Net Cash/Debt	$68M	$531M
Current Ratio (TTM)	6.34x	5.03x
Quick Ratio (TTM)	6.16x	4.96x
Debt/Equity (TTM)	0.00x	0.02x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.78	1.18
52W Performance	123.9%	-28.4%
YTD Performance	23.8%	3.8%
% from 52W High	-20.8%	-39.3%
% from 52W Low	148.3%	57.4%
Efficiency & Yields
Asset Turnover (TTM)	0.06x	0.04x
FCF Yield (TTM)	-13.1%	-15.2%
Earnings Yield (TTM)	-14.7%	-22.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-886.7	-657.3
EV/GP/RG	N/A	29.99
Ticker research	View NRIX research	View RXRX research

Valuation

P/S Ratio

RXRX

42.12x

NRIX

63.09x

EV/FCF

NRIX

-7.39x

RXRX

-5.05x

Growth & revenue

Revenue Growth TTM

RXRX

-15.1%

NRIX

-58.4%

Forward Revenue Growth

NRIX

66.6%

RXRX

31.0%

Profitability & performance

Gross Margin

RXRX

3.5%

NRIX

0.0%

ROE

RXRX

-5041.0%

NRIX

-7609.0%

FCF Yield %

NRIX

-13.1%

RXRX

-15.2%

52-Week Performance

NRIX

123.9%

RXRX

-28.4%

Detailed metrics comparison

NRIX

Nurix Therapeutics Inc

RXRX

Recursion Pharmaceuticals Inc

Market Cap

NRIX$2.32B

RXRX$2.31B

Enterprise Value

NRIX$2.25B

RXRX$1.78B

Price

NRIX$22.35

RXRX$4.36

P/E Ratio

NRIXN/A

RXRXN/A

P/S Ratio

NRIX63.09x

RXRX42.12x

EV/Sales

NRIX61.25x

RXRX32.43x

EV/EBITDA

NRIX0.00x

RXRX0.00x

P/B Ratio

NRIX5.93x

RXRX2.41x

P/FCF Ratio

NRIXN/A

RXRXN/A

EV/FCF

NRIX-7.39x

RXRX-5.05x

PEG Ratio

NRIXN/A

RXRXN/A

Forward P/E (NTM)

NRIXN/A

RXRXN/A

Forward P/S (NTM)

NRIX24.84x

RXRX44.44x

Revenue (TTM)

NRIX$37M

RXRX$55M

Revenue Growth (YoY)

NRIX-58.4%

RXRX-15.1%

Forward Rev Growth

NRIX66.6%

RXRX31.0%

Gross Margin (TTM)

NRIX0.0%

RXRX3.5%

Operating Margin (TTM)

NRIX0.0%

RXRX0.0%

EBITDA Margin (TTM)

NRIX-959.0%

RXRX-848.9%

Net Margin (TTM)

NRIX-928.4%

RXRX-945.9%

FCF Margin (TTM)

NRIX-828.3%

RXRX-642.2%

Net Income (TTM)

NRIX$-341M

RXRX$-519M

FCF (TTM)

NRIX$-305M

RXRX$-352M

EPS (TTM)

NRIX-$3.07

RXRX-$0.97

ROE (TTM)

NRIX-7609.0%

RXRX-5041.0%

ROA (TTM)

NRIX-5732.0%

RXRX-3825.0%

ROIC (TTM)

NRIX-7609.0%

RXRX-4956.0%

Cash

NRIX$68M

RXRX$546M

Debt

NRIX$0

RXRX$14M

Net Cash/Debt

NRIX$68M

RXRX$531M

Current Ratio (TTM)

NRIX6.34x

RXRX5.03x

Quick Ratio (TTM)

NRIX6.16x

RXRX4.96x

Debt/Equity (TTM)

NRIX0.00x

RXRX0.02x

Debt/Assets (TTM)

NRIX0.0%

RXRX0.0%

Interest Coverage (TTM)

NRIXN/A

RXRXN/A

Net Debt/EBITDA (TTM)

NRIX0.00x

RXRX0.00x

Beta

NRIX1.78

RXRX1.18

52W Performance

NRIX123.9%

RXRX-28.4%

YTD Performance

NRIX23.8%

RXRX3.8%

% from 52W High

NRIX-20.8%

RXRX-39.3%

% from 52W Low

NRIX148.3%

RXRX57.4%

Asset Turnover (TTM)

NRIX0.06x

RXRX0.04x

FCF Yield (TTM)

NRIX-13.1%

RXRX-15.2%

Earnings Yield (TTM)

NRIX-14.7%

RXRX-22.5%

Dividend Yield (TTM)

NRIXN/A

RXRXN/A

Rule of 40

NRIX-886.7

RXRX-657.3

EV/GP/RG

NRIXN/A

RXRX29.99

Ticker research

View NRIX research View RXRX research

Metric	NRIX Nurix Therapeutics Inc	RXRX Recursion Pharmaceuticals Inc
Market & Valuation
Market Cap	$2.32B	$2.31B
Enterprise Value	$2.25B	$1.78B
Price	$22.35	$4.36
P/E Ratio	N/A	N/A
P/S Ratio	63.09x	42.12x
EV/Sales	61.25x	32.43x
EV/EBITDA	0.00x	0.00x
P/B Ratio	5.93x	2.41x
P/FCF Ratio	N/A	N/A
EV/FCF	-7.39x	-5.05x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	24.84x	44.44x
Revenue & Growth
Revenue (TTM)	$37M	$55M
Revenue Growth (YoY)	-58.4%	-15.1%
Forward Rev Growth	66.6%	31.0%
Profitability
Gross Margin (TTM)	0.0%	3.5%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-959.0%	-848.9%
Net Margin (TTM)	-928.4%	-945.9%
FCF Margin (TTM)	-828.3%	-642.2%
Net Income (TTM)	$-341M	$-519M
FCF (TTM)	$-305M	$-352M
EPS (TTM)	-$3.07	-$0.97
ROE (TTM)	-7609.0%	-5041.0%
ROA (TTM)	-5732.0%	-3825.0%
ROIC (TTM)	-7609.0%	-4956.0%
Financial Health
Cash	$68M	$546M
Debt	$0	$14M
Net Cash/Debt	$68M	$531M
Current Ratio (TTM)	6.34x	5.03x
Quick Ratio (TTM)	6.16x	4.96x
Debt/Equity (TTM)	0.00x	0.02x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.78	1.18
52W Performance	123.9%	-28.4%
YTD Performance	23.8%	3.8%
% from 52W High	-20.8%	-39.3%
% from 52W Low	148.3%	57.4%
Efficiency & Yields
Asset Turnover (TTM)	0.06x	0.04x
FCF Yield (TTM)	-13.1%	-15.2%
Earnings Yield (TTM)	-14.7%	-22.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-886.7	-657.3
EV/GP/RG	N/A	29.99
Ticker research	View NRIX research	View RXRX research